Public Profile

Seikagaku Corporation

Seikagaku Corporation, a leading biopharmaceutical company based in Japan, has established itself as a key player in the field of regenerative medicine and orthopaedics since its founding in 1947. With its headquarters in Tokyo, Seikagaku operates extensively across Asia, Europe, and North America, focusing on the development and manufacturing of innovative products that enhance joint health and tissue regeneration. The company is renowned for its core offerings, including hyaluronic acid-based products, which are uniquely designed to treat osteoarthritis and promote joint function. Seikagaku's commitment to research and development has positioned it as a pioneer in the industry, achieving significant milestones such as the introduction of groundbreaking therapies that have transformed patient care. With a strong market presence and a dedication to advancing medical science, Seikagaku Corporation continues to lead the way in biopharmaceutical innovation.

DitchCarbon Score

How does Seikagaku Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

40

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

33

Industry Benchmark

Seikagaku Corporation's score of 40 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.

73%

Let us know if this data was useful to you

Seikagaku Corporation's reported carbon emissions

In 2024, Seikagaku Corporation reported total carbon emissions of approximately 21,000,000 kg CO2e, comprising about 8,345,000 kg CO2e from Scope 1 and about 13,023,000 kg CO2e from Scope 2. In 2023, the company’s emissions in Japan were about 22,721,000 kg CO2e for Scope 1 and 2 combined, with an additional 57,262,000 kg CO2e attributed to Scope 3 emissions globally. Seikagaku has not disclosed specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or any formal climate pledges. However, the company continues to monitor and report its emissions, indicating a commitment to transparency in its sustainability efforts. The absence of Scope 3 emissions data in some reports suggests a potential area for future focus as the company seeks to enhance its climate strategy.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

202220232024
Scope 1
8,441,000
0,000,000
0,000,000
Scope 2
14,945,000
00,000,000
00,000,000
Scope 3
-
-
-

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Seikagaku Corporation's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Seikagaku Corporation is in JP, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Seikagaku Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

SciVision Biotech Inc.

TW
Health and social work services (85)
Updated 7 days ago

Sanofi

FR
Pharmaceutical Preparation Manufacturing
Updated about 22 hours ago

Anika Therapeutics, Inc.

US
Health and social work services (85)
Updated 7 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers